| Title |
Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, July 2009
|
| DOI | 10.1007/s10549-009-0455-5 |
| Pubmed ID | |
| Authors |
Jane C. Figueiredo, Robert W. Haile, Leslie Bernstein, Kathleen E. Malone, Joan Largent, Bryan Langholz, Charles F. Lynch, Lisbeth Bertelsen, Marinela Capanu, Patrick Concannon, Ake Borg, Anne-Lise Børresen-Dale, Anh Diep, Sharon Teraoka, Therese Torngren, Shanyan Xue, Jonine L. Bernstein |
| Abstract |
The potential effects of oral contraceptive (OC) and postmenopausal hormone (PMH) use are not well understood among BRCA1 or BRCA2 (BRCA1/2) deleterious mutation carriers with a history of breast cancer. We investigated the association between OC and PMH use and risk of contralateral breast cancer (CBC) in the WECARE (Women's Environment, Cancer, and Radiation Epidemiology) Study. The WECARE Study is a population-based case-control study of 705 women with asynchronous CBC and 1,398 women with unilateral breast cancer, including 181 BRCA1/2 mutation carriers. Risk-factor information was assessed by telephone interview. Mutation status was measured using denaturing high-performance liquid chromatography followed by direct sequencing in all participants. Outcomes, treatment, and tumor characteristics were abstracted from medical records. Ever use of OCs was not associated with risk among noncarriers (RR = 0.87; 95% CI = 0.66-1.15) or BRCA2 carriers (RR = 0.82; 95% CI = 0.21-3.13). BRCA1 carriers who used OCs had a nonsignificant greater risk than nonusers (RR = 2.38; 95% CI = 0.72-7.83). Total duration of OC use and at least 5 years of use before age 30 were associated with a nonsignificant increased risk among mutation carriers but not among noncarriers. Few women had ever used PMH and we found no significant associations between lifetime use and CBC risk among carriers and noncarriers. In conclusion, the association between OC/PMH use and risk of CBC does not differ significantly between carriers and noncarriers; however, because carriers have a higher baseline risk of second primaries, even a potential small increase in risk as a result of OC use may be clinically relevant. |
Mendeley readers
The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 38 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 16% |
| Professor > Associate Professor | 5 | 13% |
| Student > Master | 5 | 13% |
| Student > Doctoral Student | 4 | 11% |
| Student > Postgraduate | 3 | 8% |
| Other | 7 | 18% |
| Unknown | 8 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 45% |
| Agricultural and Biological Sciences | 5 | 13% |
| Biochemistry, Genetics and Molecular Biology | 2 | 5% |
| Arts and Humanities | 1 | 3% |
| Nursing and Health Professions | 1 | 3% |
| Other | 2 | 5% |
| Unknown | 10 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 May 2013.
All research outputs
#5,416,216
of 22,711,242 outputs
Outputs from Breast Cancer Research and Treatment
#1,176
of 4,619 outputs
Outputs of similar age
#28,845
of 109,930 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#15
of 31 outputs
Altmetric has tracked 22,711,242 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,619 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 109,930 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 31 others from the same source and published within six weeks on either side of this one. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.